EUVIMEDEUVIMED entdecken
Open Access

Amphiregulin couples IL1RL1 + regulatory T cells and cancer-associated fibroblasts to impede antitumor immunity

Runzi Sun iD, Hongyu Zhao, David Shihong Gao iD, Andrew Ni iD, Haochen Li iD, Lujia Chen, Xinghua Lu iD, Kong Chen, Binfeng Lu iD

Science Advances · 25.08.2023 · 9 (34)

DOI: 10.1126/sciadv.add7399 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 25.08.2023. Verfasst von Runzi Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Cancer-Associated Fibroblasts. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NLM NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Regulatory T (T reg ) cells and cancer-associated fibroblasts (CAFs) jointly promote tumor immune tolerance and tumorigenesis. The molecular apparatus that drives T reg cell and CAF coordination in the tumor microenvironment (TME) remains elusive. Interleukin 33 (IL-33) has been shown to enhance fibrosis and IL1RL1 + T reg cell accumulation during tumorigenesis and tissue repair. We demonstrated that IL1RL1 signaling in T reg cells greatly dampened the antitumor activity of both IL-33 and PD-1 blockade. Whole tumor single-cell RNA sequencing (scRNA-seq) analysis and blockade experiments revealed that the amphiregulin (AREG)–epidermal growth factor receptor (EGFR) axis mediated cross-talk between IL1RL1 + T reg cells and CAFs. We further demonstrated that the AREG/EGFR axis enables T reg cells to promote a profibrotic and immunosuppressive functional state of CAFs. Moreover, AREG mAbs and IL-33 concertedly inhibited tumor growth. Our study reveals a previously unidentified AREG/EGFR-mediated T reg /CAF coupling that controls the bifurcation of fibroblast functional states and is a critical barrier for cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-Lymphocytes, RegulatoryCancer-Associated FibroblastsHumansAmphiregulinInterleukin-33CarcinogenesisCell Transformation, NeoplasticErbB ReceptorsTumor MicroenvironmentInterleukin-1 Receptor-Like 1 Protein

Substanzen

AmphiregulinInterleukin-33ErbB ReceptorsIL1RL1 protein, humanInterleukin-1 Receptor-Like 1 Protein

Autor:innen und Institutionen

  • Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.
  • Department of Biomedical informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Department of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

ORCID-Profile: Runzi Sun, David Shihong Gao, Andrew Ni, Haochen Li, Xinghua Lu, Binfeng Lu

Förderung

  • NCI NIH HHS
  • NLM NIH HHS

Zitieren

APA

Sun, R., Zhao, H., Gao, D. S., Ni, A., Li, H., Chen, L., Lu, X., Chen, K., & Lu, B. (2023). Amphiregulin couples IL1RL1 + regulatory T cells and cancer-associated fibroblasts to impede antitumor immunity. Science Advances, 9(34). https://doi.org/10.1126/sciadv.add7399

Vancouver

Sun R, Zhao H, Gao DS, Ni A, Li H, Chen L, et al. Amphiregulin couples IL1RL1 + regulatory T cells and cancer-associated fibroblasts to impede antitumor immunity. Science Advances. 2023;9(34). doi:10.1126/sciadv.add7399

BibTeX
@article{Sun2023,
  author = {Sun, Runzi and Zhao, Hongyu and Gao, David Shihong and Ni, Andrew and Li, Haochen and Chen, Lujia and Lu, Xinghua and Chen, Kong and Lu, Binfeng},
  title = {Amphiregulin couples IL1RL1 + regulatory T cells and cancer-associated fibroblasts to impede antitumor immunity},
  journal = {Science Advances},
  year = {2023},
  volume = {9},
  number = {34},
  doi = {10.1126/sciadv.add7399}
}
Kostenlos starten →